Last reviewed · How we verify
tafluprost and dorzolamide/timolol
This combination reduces intraocular pressure by increasing uveoscleral outflow via prostaglandin F analogue activity and decreasing aqueous humor production via carbonic anhydrase inhibition and beta-blockade.
This combination reduces intraocular pressure by increasing uveoscleral outflow via prostaglandin F analogue activity and decreasing aqueous humor production via carbonic anhydrase inhibition and beta-blockade. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | tafluprost and dorzolamide/timolol |
|---|---|
| Also known as | Saflutan, Taflotan, Cosopt PF |
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination |
| Target | Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Tafluprost is a prostaglandin F analogue that binds to the prostaglandin F receptor and increases uveoscleral (unconventional) outflow of aqueous humor. Dorzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor production by inhibiting carbonic anhydrase in the ciliary body. Timolol is a non-selective beta-adrenergic antagonist that further reduces aqueous humor secretion. Together, these three agents provide complementary mechanisms to lower intraocular pressure.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation/discomfort
- Blurred vision
- Increased iris pigmentation
- Eyelash growth
Key clinical trials
- From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy (NA)
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |